French pharmaceutical multinational company Sanofi Pharmaceutical headquartered in Paris, France. In 2004, the merger of Aventis and sanofi-synthelabo formed a company as ‘Sanofi-Aventis’. Later, in May 2011, the company changed its name to ‘Sanofi’. This company has acquired full membership of the European Federation of Pharmaceutical Industries and Associations, Biotechnology Industry Organization, and Pharmaceutical Research and Manufacturers of America.
The global company Sanofi Pharmaceutical provides major therapeutic segments such as oncology, cardiovascular, diabetes, central nervous system, internal medicine, thrombosis, and vaccines. The leading pharmaceutical company offers unique prescription medications like Autoimmune, Infectious disease, Metabolic, Neurology, and Pain.
In 2005, the vaccine division of Sanofi group, ‘Sanofi Pasteur’ was awarded a $97 million HHS contract. Sanofi Pasteur is a member of EuropaBio, which is Europe’s largest and most influential biotech industry group. The company anchors on Research and development and manufacturing of pharmaceutical drugs in the prescription market.
Recently, in 2018, Sanofi Pharmaceutical launched three major treatments in USA and Europe i.e. Dupixent (dupilumb) for moderate to severe asthma, Libtayo (cemiplimab) for cutaneous squamous cell carcinoma, which is the second most common skin cancer, Cablivi (caplacizumab), for acquired thrombotic thrombocytopenic purpura, a rare blood clotting disorder.